GLOW, KLOW and Wolverine are names, not products with a fixed formula. Sellers use them for vials that combine two to four peptides, and the exact ingredients and amounts are set by each seller. The lists below are the ingredients these blends are most commonly sold with:
- GLOW: GHK-Cu, BPC-157 and TB-500
- KLOW: GHK-Cu, BPC-157, TB-500 and KPV
- Wolverine stack: BPC-157 and TB-500
GLOW blend
GLOW is usually sold as a single vial of GHK-Cu, BPC-157 and TB-500, marketed for skin, hair and recovery. The amount of each ingredient is fixed by the seller, and sellers do not all use the same amounts. The copper in GHK-Cu turns the reconstituted solution blue.
| Stated ingredient and evidence tier | What the evidence is | Key source |
|---|---|---|
| GHK-CuTier B · Some human evidence | Human studies support topical use on skin. Injected use has been studied far less formally. | Review, 2018 |
| BPC-157Tier D · Mostly preclinical | Extensive animal and laboratory research, very limited human trials. Prohibited by the World Anti-Doping Agency. | Review, 2019 |
| TB-500Tier D · Mostly preclinical | Tissue-repair findings come from animal and laboratory research, and human data is limited. Prohibited by the World Anti-Doping Agency. | Human trial, 2010 |
KLOW blend
KLOW is sold as GLOW with a fourth peptide added: KPV, a fragment of the hormone alpha-MSH studied for anti-inflammatory effects. Seller listings name the same four ingredients but differ in the amounts.
| Stated ingredient and evidence tier | What the evidence is | Key source |
|---|---|---|
| GHK-CuTier B · Some human evidence | Human studies support topical use on skin. Injected use has been studied far less formally. | Review, 2018 |
| BPC-157Tier D · Mostly preclinical | Extensive animal and laboratory research, very limited human trials. Prohibited by the World Anti-Doping Agency. | Review, 2019 |
| TB-500Tier D · Mostly preclinical | Tissue-repair findings come from animal and laboratory research, and human data is limited. Prohibited by the World Anti-Doping Agency. | Human trial, 2010 |
| KPVTier D · Mostly preclinical | Anti-inflammatory effects reported in animal models of colitis and skin inflammation. Human clinical data is limited. | Preclinical, 2008 |
Wolverine stack
The Wolverine stack, named after the comic-book character's fast healing, is BPC-157 paired with TB-500. Some sellers offer it as one blended vial and others as two separate vials, and some add further compounds under the same name.
| Stated ingredient and evidence tier | What the evidence is | Key source |
|---|---|---|
| BPC-157Tier D · Mostly preclinical | Extensive animal and laboratory research, very limited human trials. Prohibited by the World Anti-Doping Agency. | Review, 2019 |
| TB-500Tier D · Mostly preclinical | Tissue-repair findings come from animal and laboratory research, and human data is limited. Prohibited by the World Anti-Doping Agency. | Human trial, 2010 |
What the research says about the blends
No published study has tested GLOW, KLOW or the Wolverine combination. Every finding cited for them comes from research on a single ingredient, and most of that is animal or laboratory work: BPC-157, TB-500 and KPV are all tier D on our tier list.
The human evidence for GHK-Cu, the one tier B ingredient, supports topical use on skin. These blends are sold as powder vials for reconstitution, a different route from the one studied in people.
Combining compounds also adds questions that single-ingredient studies cannot answer, such as whether the peptides stay stable together in one solution. Long-term human safety of the combinations is unstudied.
How the blends are sold
Blends are sold only as research chemicals, labeled as not for human use. None is FDA-approved, and no regulator checks what is in a vial or in what amounts. BPC-157 is classified by the FDA as a Category 2 bulk drug substance, and both BPC-157 and TB-500 are on the World Anti-Doping Agency's prohibited list.
Sources
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Pickart L et al. International Journal of Molecular Sciences, 2018. Review
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Gwyer D et al. Cell and Tissue Research, 2019. Review
- The effect of thymosin treatment of venous ulcers. Guarnera G et al. Annals of the New York Academy of Sciences, 2010. Human trial
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Kannengiesser K et al. Inflammatory Bowel Diseases, 2008. Preclinical
Frequently asked questions
What is in the GLOW peptide blend?
GLOW is usually sold as GHK-Cu, BPC-157 and TB-500 in one vial. The amounts are set by each seller and are not standardized.
What is the KLOW peptide?
KLOW is sold as GLOW plus KPV: GHK-Cu, BPC-157, TB-500 and KPV in one vial. Seller listings differ in the amounts.
What is the Wolverine peptide stack?
An informal name for BPC-157 and TB-500 used together, sold as one blended vial or as two separate vials. Some sellers add other compounds under the same name.
Has any study tested these peptide blends?
No. No published study has tested GLOW, KLOW or the Wolverine combination. The research cited for them is on single ingredients, mostly in animals and laboratory models.
Are peptide blends FDA-approved?
No. They are sold only as research chemicals labeled as not for human use, and no regulator checks their contents.
Look up any compound in the app
PeptidesAI covers 70 compounds with the same evidence-first approach, plus a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store